MDFA welcomes the release of a white paper, “Advocating for Improved Treatment and Outcomes for Wet age-related macular degeneration”.
Read MoreMDFA welcomes the release of a white paper, “Advocating for Improved Treatment and Outcomes for Wet age-related macular degeneration”.
Read MoreMacular Disease Foundation Australia is angry with the ambiguous amendments to the National Disability Insurance Scheme (NDIS).
Read MoreMDFA is calling on the Federal Government to rethink how older Australians will be cared for given the NDIS excludes people who acquire a disability at the age of 65 and over.
Read MoreThe Foundation continues its campaign against unfairness in the National Disability Insurance Scheme.
Read MoreThe Foundation welcomes the decision to allow switching of age-related macular degeneration drugs Eylea and Lucentis.
Read MoreA powerful ‘How’s your macula?’ television advertisement has been produced by the Macular Degeneration Foundation.
Read MoreThere has been a big community response to the Foundation’s campaign to allow AMD drug “switching”.
Read MoreInternational experts met in Sydney in 2012 to develop a road map for the management of wet age-related macular degeneration.
Read MoreWith a new treatment for wet AMD coming on the market, drug switching between Lucentis and Eylea should be allowed.
Read More